Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth

Executive Summary

Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.

Advertisement

Related Content

‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Helsinn Family Business Establishes $50m Start-Up Investment Fund
VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings
Viventia's Cancer Ambitions Go To Eleven
Sage Drug Could Help Take Stigma Out Of Postpartum Depression
Patient Registries Prove Value As Drug Development Tools
Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?
Biotech Stars And Startups Raise $168m In Venture Cash
Biotech IPO Window Closed In November As Returns And Prices Plunged
Third Rock raises $516m for early-stage venture deals

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel